BrainQ, BYON8, Sydnexis
Healthtech Startup BYON8 Raises USD 1.5 Mn To Scale Across Africa
BYON8, an online doctor digital health platform, has raised USD 1.5 Mn in seed capital to help in its expansions across Africa. The round included Danish early tech investor, People Ventures, and current investors T&W Holding and Jellyfish Invest.
The startup launched a new medical diagnostic software based on mathematical algorithms and medical AI, converting patient data into calculated diagnostic proposals, improving the healthcare process and customer experiences regardless of financial status.
BYON8 was founded in the fall of 2015 in Sweden by doctors, mathematicians and programmers. The goal was to make high quality healthcare more accessible, affordable and equal by digitalizing healthcare on an individual level. The BYON8 app was developed as a result of over 4 years of medical research and development launching in early 2020.
https://weetracker.com/2021/08/12/healthtech-startup-byon8-raises-usd-1-5-mn-to-scale-across-africa/ https://www.byon8.com/byon8-overviewPBS Biotech Raises $10M in Funding
PBS Biotech, a Camarillo, CA-based single-use bioreactor manufacturer, closed a $10M funding round.
BroadOak Capital Partners made the investment.
The company intends to use the funds to expand and industrialize its portfolio of single-use bioreactor systems and contract process development services.
Led by Brian Lee, CEO, PBS Biotech is a manufacturer of single-use bioreactor systems. The company utilizes proprietary Vertical-WheelTM technology to achieve unique mixing properties and environmental conditions for cell therapy products. In addition, the company operates an in-house bioprocess R&D facility to offer process expertise and development services to assist cell therapy customers in scaling up from research phases to clinical and commercial phases.
PBS Biotech systems are used by over 200 customers ranging from small-scale research and development groups to large-scale manufacturing groups. The company will look to secure and expand its product line over the next several years to support existing and future customers through clinical trials to commercialization.
PBS Biotech Raises $10M in Funding
PBS Biotech, a Camarillo, CA-based single-use bioreactor manufacturer, closed a $10M funding round
Debut Biotech Raises $22.6M in Series A Funding
Debut Biotech, a San Diego, CA-based developer of a biomanufacturing platform harnessing cell-free enzymes, raised $22.6M in Series A financing.
The round was led by Material Impact with participation from Cultivian Sandbox Ventures, Fine Structure Ventures, ACVC Ventures, Humboldt Fund, Cantos Ventures, as well as existing investors including KdT Ventures.
The company will use the funds to commercialize ingredients developed from its proprietary cell-free biomanufacturing platform.
Led by CEO Joshua Britton, Debut Biotech has developed a biomanufacturing platform which utilizes cell-free approaches to produce rare, high-value and novel compounds and improve traditional ingredient manufacturing. It has applications across various industries from food and wellness products to cosmetics, colors, therapeutics and other industrial applications. In order to scale the commercialization of its technology and expand into new products, Debut Biotech will expand its footprint to a 26,000 square foot facility in San Diego and triple the size of its team across locations in San Diego and Atlanta. These facility investments will enable manufacturing to be done entirely in the United States.
Debut Biotech Raises $22.6M in Series A Funding
Debut Biotech, a San Diego, CA-based developer of a biomanufacturing platform harnessing cell-free enzymes, raised $22.6M in Series A financing
Visus Therapeutics Raises $20M in Funding
Visus Therapeutics, Inc., a Seattle, WA- and and Orange County, Calif.,-based based clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world, raised $20m in funding.
The round was led by LSP in Amsterdam, with participation from Sage Partners of Hong Kong, Johnson & Johnson Innovation -JJDC, Inc. and other inside investors. In conjunction with this financing, John de Koning, Ph.D., a General Partner at LSP, has joined the Company’s Board of Directors.
The company intends to use the funds to advance its clinical and commercial efforts for lead asset BRIMOCHOL™ under investigation for presbyopia as well as new research and development activities in its drug development pipeline.
Led by Ben Bergo, co-founder and chief executive officer, Visus Therapeutics is asvancing BRIMOCHOL, an investigational drug designed to be a once-daily eye drop to correct for the loss of near vision associated with presbyopia. It is a proprietary formulation that combines two FDA-approved pharmaceuticals: carbachol and brimonidine. BRIMOCHOL has been studied in more than 200 patients across six clinical studies. Topline data from a Phase 2 clinical study evaluating BRIMOCHOL for the treatment of presbyopia are expected in the second half of 2021 and, pending affirmative results, the company plans to immediately initiate pivotal Phase 3 studies.
Visus Therapeutics Raises $20M in Funding | FinSMEs
Visus Therapeutics, Inc., a Seattle, WA- and and Orange County, Calif.,-based based clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world, raised $20m in funding
Beckley Psytech Closes $80M Series B Funding
Beckley Psytech, an Oxford, England-based private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, closed an $80m Series B financing.
The round was led by Integrated, with participation from Prime Movers Labs, Adage Capital Management, Palo Santo; Delphi VC; Leafy Tunnel; Negev Capital; and existing investor Bicycle Day Ventures.
The company intends to use the funds to complete the ongoing Phase 1b trial with low-dose psilocybin in patients suffering from SUNHA, a rare and debilitating headache condition estimated to affect 45,000 people in the US and Europe, and to initiate a Phase 1 dose-ranging study on a novel formulation of intranasal 5-MeO-DMT before starting a Phase 2 trial in Treatment Resistant Depression, and expand its pipeline with new, unique and proprietary psychedelic compounds.
Led by Cosmo Feilding Mellen, CEO, Beckley Psytech is a clinical stage company dedicated to helping patients suffering from neurological and psychiatric disorders by developing a broad pipeline of psychedelic compounds in rare and more common diseases.
Beckley Psytech Closes $80M Series B Funding
Beckley Psytech, an Oxford, England-based private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, closed an $80m Series B financing
Ultromics Raises $33M in Series B Funding
Ultromics, an Oxford, UK-based company focused on advancing AI enabled cardiovascular imaging solutions, raised $33M in series B funding.
The round was led by Blue Venture Fund with participation from Optum Ventures, GV and Oxford Sciences Innovation.
The company intends to use the funds to accelerate the use of AI-enabled echocardiograms to improve patient care, and bring improved diagnostic quality and resource savings to hospitals.
Led by Dr. Ross Upton, Ultromics provides automated software powered by AI that allows clinicians to make fast, accurate decisions when using ultrasound images to diagnose cardiovascular disease. The EchoGo Core and EchoGo Pro platforms deliver accurate assessments of heart function that support the diagnosis of coronary artery disease, heart failure and amyloidosis.
Ultromics Raises $33M in Series B Funding
Ultromics, an Oxford, UK-based company focused on advancing AI enabled cardiovascular imaging solutions, raised $33M in series B funding
Reify Health Raises $220M in Series C Funding
Reify Health, a Boston, MA-based clinical trials optimization software provider, raised $220m in Series C funding.
The round, which brought the valuation to $2.2 billion, was led by Coatue Management, with participation from ICONIQ Growth and Adams Street Partners, as well as existing investors Sierra Ventures and Battery Ventures.
Led by Ralph Passarella, CEO, Reify Health operates two business entities, StudyTeam and Care Access.
StudyTeam delivers a technology platform for optimizing patient recruitment and enrollment, and is used by top-20 global biopharma companies such as Amgen, AstraZeneca, and Eli Lilly and Company, and approximately 4,000 research sites across 65 countries. Care Access is a decentralized research organization that brings clinical trial infrastructure directly to patients, healthcare providers, and communities.
The company intends to use the funds to accelerate growth and expansion of both business entities.
Reify Health Raises $220M in Series C Funding | FinSMEs
Reify Health, a Boston, MA-based clinical trials optimization software provider, raised $220m in Series C funding
GentiBio Raises $157M in Series A Financing
GentiBio, Inc., a Boston, MA-based biotherapeutics company developing engineered regulatory T cells (Tregs) therapies for immunology, closed a $157m Series A financing.
The round was led by Matrix Capital Management with participation from Avidity Partners, JDRF T1D Fund, OrbiMed, RA Capital Management, and Novartis Venture Fund, and Seattle Children’s Research Institute.
The company intends to use the funds to advance its potential functional cure for Type 1 Diabetes (T1D) to the clinic alongside multiple other pipeline programs in chronic autoimmunity and autoinflammation.
Led by Adel Nada, M.D., M.S., President and Chief Executive Officer, GentiBio is a biotherapeutics company advancing engineered regulatory T cells programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. Its proprietary autologous and allogeneic engineered Tregs platform integrates key complementary technologies needed to (re)establish immune tolerance and overcome major limitations in existing regulatory T cell therapeutics.
GentiBio Raises $157M in Series A Financing | FinSMEs
GentiBio, Inc., a Boston, MA-based biotherapeutics company developing engineered regulatory T cells (Tregs) therapies for immunology, closed a $157m Series A financing
Mahana Therapeutics Raises $61M in Series B Financing
Mahana Therapeutics, a San Francisco, CA-based developer of prescription digital therapeutics designed to empower patients with chronic health conditions, raised $61m in Series B financing.
The round was led by JAZZ Venture Partners and Gurnet Point Capital with participation from new and existing investors Main Street Advisors, KKCG and Lux Capital. Sophie Kornowski of Gurnet Point and Meghan Reynolds of JAZZ have joined the Mahana Therapeutics Board of Directors.
The company will use the funds to launch the FDA-cleared prescription digital therapeutic Mahana™ IBS and accelerate development of several digital therapeutics for chronic health conditions.
Led by Steven Basta, chief executive officer, Mahana Therapeutics is a developer of prescription digital therapeutics that are designed to empower patients with chronic conditions. The company’s first product, Mahana IBS, is a digital therapeutic that has demonstrated effectiveness in a 558-patient clinical trial in individuals with irritable bowel syndrome and has received FDA clearance for that treatment.
Mahana Therapeutics Raises $61M in Series B Financing | FinSMEs
Mahana Therapeutics, a San Francisco, CA-based developer of prescription digital therapeutics designed to empower patients with chronic health conditions, raised $61m in Series B financing
Sydnexis Raises $45M in Series B Funding
Sydnexis, a San Diego CA-based biopharmaceutical company, raised $45M in Series B funding.
The round was led by Visionary Ventures, Blue Stem Capital, and SC Master Fund with participation from RA Capital Management, Longitude Capital and Medicxi. In conjunction with the financing, Jeffry Weinhuff, Managing Partner, Visionary Ventures, Richard L. Lindstrom, MD, Tyler Stowater, Partner, Bluestem Capital, and Gregory Grunberg, MD, Managing Director, Longitude Capital will join Sydnexis’ board alongside existing directors Zach Scheiner, PhD, Principal, RA Capital Management, and Kenneth J Widder, MD Chairman and CEO.
Led by Kenneth J. Widder, MD, Chief Executive Officer, Sydnexis is a clinical stage pharmaceutical company focused on the development of a novel proprietary formulation of low dose atropine for the treatment of myopia.
The company intends to use the funds to advance its lead candidate, SYD-101, through completion of the fully enrolled pivotal Phase 3 STAAR study for the treatment of progressive myopia in children. In this study, Sydnexis is evaluating two different concentrations of its proprietary atropine formulation SYD-101 (0.01% and 0.03%) versus a placebo control group. SYD-101 is designed to be a best-in-class product with maximum efficacy, comfort and 3-year stability at room temperature, all important product attributes when developing drugs for use in children.
Sydnexis Raises $45M in Series B Funding | FinSMEs
Sydnexis, a San Diego CA-based biopharmaceutical company, raised $45M in Series B funding
BrainQ Raises $40M in Funding
BrainQ, an Israeli stroke therapy technology company, raised $40M in funding.
The round was led by Hanaco Ventures, with participation from Dexcel Pharma, and Peregrine Ventures, adding to support already secured from existing investors OurCrowd, Norma, Sailing Capital, IT Farm, Millhouse and Qure.
The company intends to use the funds for a multicenter pivotal trial for its technology for ischemic stroke survivors in selected US hospitals.
Led by Co-Founder and CEO Yotam Drechsler, BrainQ has developed investigational neurorecovery technology which aims to reduce disability and promote neurorecovery for stroke victims. Using a Brain Computer Interface-based approach, the company’s frequency-tuned low intensity electromagnetic field therapy is designed to operate based on biological insights retrieved from brainwaves using explanatory machine learning tools. These insights are aimed at imitating the natural processes of neural network synchronization and promoting recovery processes. The system is designed to allow for scalable and decentralized care via a portable, non-invasive wearable device that is cloud-connected with integrated telemedicine tools that enable remotely monitored sessions through an app.
